Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Hiscox appoints Peter Clarke as its new chair

(Sharecast News) - Hiscox announced the appointment of Peter Clarke as chair designate on Thursday, with effect from 1 June, subject to regulatory approval. The FTSE 100 international specialist insurer said he would succeed Colin Keogh on 1 July.

It said Clarke would bring extensive leadership experience across FTSE-listed financial services firms, including two decades at Man Group, where he served as both chief financial officer and chief executive.

He had held a number of board-level roles, including as chair of Lancashire Insurance Holdings and non-executive director at Axa Investment Managers and Sainsbury's Bank.

Clarke currently chairs Redwheel and sits on the boards of Lombard Odier Asset Management in the US, Europe and Switzerland.

"After an extensive search I am pleased to have led the process that resulted in the nominations and governance committee selecting Peter as the board's next chair," said interim chair Colin Keogh, who will step down from the board on 1 July.

"Peter will be a great addition to the board, and the business will benefit immensely from his vast experience, particularly as it relates to Bermuda-domiciled insurance carriers."

At 0847 BST, shares in Hiscox were up 0.48% at 1,256p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.